Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arginine-vasopressin + corticotropin-releasing factor
- Development stage
- Preclinical
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination of two endogenous peptide hormones—arginine-vasopressin (AVP) and corticotropin-releasing factor (CRF)—administered together to study or modulate the hypothalamic-pituitary-adrenal (HPA) axis. Arginine-vasopressin acts as an antidiuretic and vasoconstrictor, while also potentiating the release of adrenocorticotropic hormone (ACTH) from pituitary corticotrophs. Corticotropin-releasing factor is a primary stimulator of ACTH secretion. When administered in combination, AVP and CRF act synergistically to greatly enhance ACTH release compared to either agent alone[1][3][4][6]. This synergy has been used experimentally to probe HPA axis function in humans and animals, with potential applications in understanding stress responses and disorders involving adrenal insufficiency.
- Other names
- AVP + CRFargipressin + corticotropin-releasing hormoneantidiuretic hormone + CRH
02
Targets
Oxytocin receptorAVPR1A (Arginine vasopressin receptor 1A)AVPR1B (Vasopressin V1b Receptor)CRHR2 (Corticotropin-releasing hormone receptor 2)CRHR1 (Corticotropin-releasing factor receptor 1)
Beyond the preview
Go deeper on arginine-vasopressin + corticotropin-releasing factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arginine-vasopressin + corticotropin-releasing factor.